• FCC approves experimental trials by Anterix and Lynk Global for satellite direct to device communications using licensed 900 MHz spectrum.
• Trials aim to support secure, resilient connectivity for critical infrastructure sectors, including utilities, logistics, and transportation.
• The FCC decision positions Anterix to test integrated satellite and terrestrial wireless offerings alongside its existing private wireless focus.

For investors watching NasdaqCM:ATEX, this FCC approval comes with the stock at a recent share price of $58.78, following a 39.3% return over the past 30 days and a 164.4% return year to date. The stock has also recorded a 104.4% return over the past year and an 80.4% return over three years, with a value score of 4 provided here as context rather than a rating.

The new trials bring Anterix into direct to device satellite testing that could broaden how its 900 MHz spectrum is used for nationwide and resilient coverage. Readers may want to watch how results from these experiments shape potential offerings to critical infrastructure customers and whether this collaboration with Lynk Global leads to further commercial arrangements.

Stay updated on the most important news stories for Anterix by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Anterix.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$58.78, the stock trades about 6% above the US$55.33 analyst target, within the 10% band that looks roughly in line with consensus.
• ✅ Simply Wall St Valuation: Simply Wall St’s model suggests the stock trades about 63.4% below its estimated fair value, which screens as materially undervalued in that framework.
• ✅ Recent Momentum: A 39.3% return over the last 30 days shows strong short term momentum into this FCC trial news.

There is only one way to know the right time to buy, sell or hold Anterix. Head to Simply Wall St's company report for the latest analysis of Anterix's Fair Value..

Key Considerations

• 📊 The FCC trial approval ties Anterix’s 900 MHz spectrum to a direct to device satellite use case, which could be important for how investors frame its telecom role with critical infrastructure customers.
• 📊 Investors may want to monitor how trial results, any follow on agreements with Lynk Global, and the gap between the current US$58.78 price and the US$55.33 target evolve alongside Simply Wall St’s valuation output.
• ⚠️ Major risks include earnings quality concerns and forecasts that point to declining earnings over the next three years, which may influence how much weight is placed on current profitability.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Anterix analysis. Alternatively, you can check out the community page for Anterix to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.